Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Express Scripts
Dow
Merck
Harvard Business School

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,877,021

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 5,877,021
Title: B7-1 targeted ribozymes
Abstract:Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1.
Inventor(s): Stinchcomb; Dan T. (Boulder, CO), Jarvis; Thale (Boulder, CO), McSwiggen; James (Boulder, CO)
Assignee: Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:08/585,684
Patent Claims:1. An enzymatic nucleic acid molecule which specifically blocks synthesis and/or expression of an mRNA encoding B7-1.

2. The enzymatic nucleic acid molecule of claim 1, wherein, the binding arms of said enzymatic nucleic acid molecule comprise sequences complementary to any of sequences defined as Seq ID Nos 1-299 and 599-896.

3. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hammerhead motif.

4. The enzymatic nucleic acid molecule of claim 1, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, VS nucleic acid or RNaseP nucleic acid motif.

5. The enzymatic nucleic acid molecule of any of claim 1, wherein said enzymatic nucleic acid molecule comprises between 12 and 100 bases complementary to the RNA of said region.

6. The enzymatic nucleic acid of claim 5, wherein said enzymatic nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA of said region.

7. A mammalian cell including an enzymatic nucleic acid molecule of claim 1.

8. The mammalian cell of claim 7, wherein said mammalian cell is a human cell.

9. An expression vector comprising a nucleic acid sequence encoding the enzymatic nucleic acid molecule of claim 1, in a manner which allows expression and/or delivery of that enzymatic RNA molecule within a mammalian cell.

10. A mammalian cell including the expression vector of claim 9.

11. The mammalian cell of claim 10, wherein said mammalian cell is a human cell.

Details for Patent 5,877,021

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Ribozyme Pharmaceuticals, Inc. (Boulder, CO) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKesson
Harvard Business School
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.